Drugs / MK-8291
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02336555 | Mar 2015 → Feb 2016 | postherpetic neuralgia | Merck Sharp & Dohme LLC | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02336555 ↗ |
| Route | Oral | “orally administered 10 mg MK-8291” NCT02336555 ↗ |